Mycophenolate mofetil for the treatment of juvenile onset SLE: A multicenter study

Lupus

Volumn 18, Issue 2, 2009, Pages 139-143

  Falcini, F ^a,e   Capannini, S ^a   Martini, G ^b   La Torre, F ^c   Vitale, A ^c   Mangiantini, F ^d   Nacci, F ^a   Cerinic, M M ^a   Cimaz, R ^d   Zulian, F ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e not available   (Italy)

Author keywords

Juvenile SLE; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 65349114756     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308094999     Document Type: Article

References (30)

1. Bardsley-Elliot, A, Noble, S, Foster, RH. Mycophenolate mofetil: a review of its use in the management of solid organ transplantation. Bio Drugs 1999; 12: 363-410.
2. Eugui, EM, Almquist, S, Muller, CD, Allison, AC. Lymphocyte of selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-173.
3. Quiroz, Y, Herrera-Acosta, J, Johnson, RJ, Rodriguez-Iturbe, B. Mycophenolate mofetil treatment in conditions different from organ transplantation. Transplant Proc 2002; 34: 2523-2526.
4. Chan, TM, Li, FK, Tang, CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
5. Ginzler, EM, Dooley, MA, Aranow, C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
6. Pisoni, CN, Sanchez, FJ, Karim, Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
7. Wang, J, Hu, W, Xie, H, et al. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus 2007; 16: 707-712.
8. Sahin, GM, Sahin, S, Kantarci, G, Ergin, H. Mycophenolate mofetil treatment for therapy-resistant glomerulopathies. Nephrology (Carlton) 2007; 12: 285-288.
9. Contreras, G, Sosnov, J. Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol 2007; 2: 879-882.
10. Borba, EF, Guedes, LK, Christmann, RB, Figueiredo, CP, Gonçalves, CR, Bonfá, E. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 2006; 26: 1078-1083.
11. Buratti, S, Szer, IS, Spencer, CH, Bartosh, S, Reiff, A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108.
12. Fu, YF, Liu, GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001; 55: 318-321.
13. Carreno, L, Lopez-longo, FJ, Gonzalez, CM, Monteagudo, I. Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs 2002; 4: 241-256.
14. Ranchin, B. New treatment strategies for proliferative lupus nephritis: keep children in mind. Lupus 2007; 20: 1-8.
15. Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
16. Bombardier, C, Gladman, DD, Urowitz, MB, Caron, D, Chang, CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
17. Baqi, N, Moazami, S, Singh, A, Ahamad, H, Balachandra, S, Tejani, A. Lupus nephritis in children: a longitudinal study of prognosis factors and therapy. J Am Soc Nephrol 1996; 7: 924-932.
18. Hagelberg, S, Lee, Y, Bargman, J, et al. Long term follow-up of childhood lupus nephritis. J Rheumatol 2002; 29: 2635-2642.
19. Bogdanovic, R, Nikolic, V, Pasic, S, et al. Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol 2004; 19: 36-44.
20. Macdermott, EJ, Adams, A, Lehman, TJ. Systemic lupus erythematosus in children: current and emerging therapies. Lupus 2007; 16: 677-683.
21. Zhu, B, Chen, N, Lin, Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007; 22: 1933-1942.
22. Sahin, GM, Sahin, S, Kantarci, G, Ergin, H. Mycophenolate mofetil treatmentfor therapy-resistant glomerulopathies. Nephrol 2007; 12: 285-288.
23. Walsh, M, James, M, Jayne, D, Tonelli, M, Manns, BJ, Hemmelgarn, BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-975.
24. Sixdorf, U, Bauer, H, Märker-Hermann, E. Manifestation of diffuse proliferative lupus nephritis in a patient treated with long-term mycophenolate mofetil. Dtsch Med Wochenschr 2006; 131: 2266-2269.
25. Pisoni, CN, Obermoser, G, Cuadrado, MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23: 393-396.
26. Mak, A, Mok, CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14: 856-858.
27. Mok, CC. Mycophenolatemofetil for non-renalmanifestations of systemic lupus erythematosous: a systematic review. Scand J Rheumatol 2007; 36: 329-337.
28. Szyper-Kravitz, M, Sheinberg, P, Sidi, Y, Schiffenbauer, Y, Trubniykov, E, Shoenfeld, Y. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. Int Arch Allergy Immunol 2005; 138: 334-336.
29. Dasgupta, N, Gelber, AC, Racke, F, Fine, DM. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005; 14: 910-913.
30. Draper, HM. Depressive disorder associated with mycophenolate mofetil. Pharmacotherapy 2008; 28: 136-139.